» Articles » PMID: 18779727

Low-grade Serous Carcinoma of the Ovary Displaying a Macropapillary Pattern of Invasion

Overview
Date 2008 Sep 10
PMID 18779727
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive micropapillary serous carcinoma (MPSC) also designated "low-grade serous carcinoma" (LGSC) of the ovary is characterized by small micropapillae that infiltrate underlying tissue (ovarian stroma). On occasion these tumors in addition to the micropapillae contain large macropapillae lined by bland epithelium. In rare cases, the entire tumor is composed of macropapillae. In these cases, the question of whether this is an invasive carcinoma or an unusual type of adenofibroma has been raised. The goal of this study was to describe this unusual macropapillary pattern of invasion in LGSC. Cases of LGSC containing macropapillae were retrieved from the files of the Johns Hopkins Hospital. In addition to a detailed morphologic analysis, the mutational status of KRAS and BRAF in the macropapillary, noninvasive, and invasive MPSC components was analyzed by nucleotide sequencing. There were 14 cases containing macropapillae (11 cases of LGSC, 2 cases of atypical proliferative serous tumor (APST) with microinvasion, and 1 case of APST with a focus of LGSC with macropapillae in perivaginal soft tissue). In 3 cases, extraovarian metastases contained macropapillae. Molecular analysis of the primary tumor components (macropapillary, noninvasive, and invasive MPSC and/or APST) was performed in 7 cases and of a lymph node metastasis with macropapillae in 1 case. The identical KRAS mutation was detected in all of the analyzed components of the primary ovarian tumors in 4 cases. In one of these cases, macropapillae in the lymph node metastasis contained a KRAS mutation identical to the primary tumor. The BRAF mutation identified in 1 case was identical in all components of the ovarian tumor. The identical mutations in the macropapillae and the other tumor components in each case indicate that they are clonally related. The finding of macropapillae within lymph nodes supports the interpretation that the macropapillary component is another manifestation of invasion in LGSC. The recognition of this pattern is important, especially in cases when a tumor is composed entirely of macropapillae.

Citing Articles

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.

Hollis R, Thomson J, van Baal J, Ilenkovan N, Churchman M, Van de Vijver K Sci Rep. 2023; 13(1):7681.

PMID: 37169775 PMC: 10175560. DOI: 10.1038/s41598-023-34627-5.


Architectural Histopathological Changes in Ovarian Serous Carcinomas.

Dochit C, Stepan A, Margaritescu C, Simionescu C Curr Health Sci J. 2019; 44(4):356-361.

PMID: 31123612 PMC: 6421477. DOI: 10.12865/CHSJ.44.04.06.


BRAF mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.

Turashvili G, Grisham R, Chiang S, DeLair D, Park K, Soslow R Histopathology. 2018; 73(3):438-443.

PMID: 29770477 PMC: 6105553. DOI: 10.1111/his.13651.


Advanced stage micropapillary serous borderline ovarian tumor in a postmenopausal woman: a case report.

Gungor T, Kaba M, Baser E, Yalcin H, Bayramoglu H, Besli M J Turk Ger Gynecol Assoc. 2014; 13(3):208-11.

PMID: 24592040 PMC: 3939243. DOI: 10.5152/jtgga.2012.30.


[Update on gynecopathology].

Schmidt D Pathologe. 2012; 34(1):25-33.

PMID: 23263439 DOI: 10.1007/s00292-012-1705-6.


References
1.
Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

2.
Sieben N, Macropoulos P, Roemen G, Kolkman-Uljee S, Fleuren G, Houmadi R . In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004; 202(3):336-40. DOI: 10.1002/path.1521. View

3.
Kindelberger D, Lee Y, Miron A, Hirsch M, Feltmate C, Medeiros F . Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007; 31(2):161-9. DOI: 10.1097/01.pas.0000213335.40358.47. View

4.
Bell K, Smith Sehdev A, Kurman R . Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001; 25(4):419-32. DOI: 10.1097/00000478-200104000-00001. View

5.
Crum C, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y . Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007; 5(1):35-44. PMC: 1855333. DOI: 10.3121/cmr.2007.702. View